(NURE) Nuveen Short-Term REIT - Ratings and Ratios

Exchange: BATS • Country: USA • Currency: USD • Type: Etf • ISIN: US67092P7069

Real Estate, REITs, Equity, Investment, Assets

Description: NURE Nuveen Short-Term REIT

Nuveen Short-Term REIT ETF (BATS:NURE) is an exchange-traded fund that focuses on investing at least 80% of its net assets and borrowings in Real Estate Investment Trusts (REITs) that meet specific criteria. The underlying index is a subset of the Dow Jones U.S. Select REIT Index, comprising equity REITs listed on U.S. national securities exchanges, deriving at least 75% of their revenue from owning and operating real estate assets, and having a minimum market capitalization of $200 million.

The funds investment strategy is centered around REITs that are primarily involved in the ownership and operation of real estate assets, providing a relatively focused exposure to the real estate sector. As a non-diversified fund, NURE may have a higher concentration risk compared to diversified funds, which could result in higher volatility.

Analyzing the , we observe that NUREs last price is $30.70, with short-term moving averages (SMA20 and SMA50) indicating a slight uptrend, as the price is above both the $30.24 and $30.09 levels. However, the long-term SMA200 at $31.64 suggests that the ETF is currently trading below its longer-term trend. The Average True Range (ATR) of $0.60, or 1.97%, indicates moderate volatility. Considering the 52-week high and low of $34.16 and $26.98, respectively, NURE is currently trading near the middle of its recent price range.

Combining the insights from and , we can infer that NUREs Assets Under Management (AUM) of $44.42 million may limit its liquidity and potentially impact its ability to efficiently track its underlying index. However, its current price action and technical indicators suggest a potential for short-term gains if the uptrend continues. A forecast based on these factors could be that NURE may experience a short-term price increase, potentially targeting the $31.64 SMA200 level, provided that the overall real estate sector and broader market conditions remain favorable.

To validate this forecast, it is crucial to monitor the funds tracking error, changes in AUM, and shifts in the underlying index composition. Additionally, keeping a close eye on interest rates, real estate market trends, and overall economic conditions will be essential in assessing NUREs future performance.

NURE ETF Overview

Market Cap in USD 34m
Category Real Estate
TER 0.35%
IPO / Inception 2016-12-19

NURE ETF Ratings

Growth Rating 3.62
Fundamental -
Dividend Rating 60.7
Rel. Strength -9.50
Analysts -
Fair Price Momentum 26.73 USD
Fair Price DCF -

NURE Dividends

Dividend Yield 12m 4.22%
Yield on Cost 5y 6.26%
Annual Growth 5y 3.92%
Payout Consistency 82.8%
Payout Ratio %

NURE Growth Ratios

Growth Correlation 3m -34.7%
Growth Correlation 12m -84.2%
Growth Correlation 5y 23.9%
CAGR 5y 7.32%
CAGR/Max DD 5y 0.20
Sharpe Ratio 12m -0.03
Alpha -22.11
Beta 0.582
Volatility 22.15%
Current Volume 1.3k
Average Volume 20d 3.2k
Stop Loss 27.5 (-3.1%)

What is the price of NURE shares?

As of August 13, 2025, the stock is trading at USD 28.38 with a total of 1,300 shares traded.
Over the past week, the price has changed by -0.86%, over one month by -5.83%, over three months by -6.93% and over the past year by -7.54%.

Is Nuveen Short-Term REIT a good stock to buy?

Neither. Based on ValueRay´s Analyses, Nuveen Short-Term REIT is currently (August 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 3.62 and therefor a technical neutral rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NURE is around 26.73 USD . This means that NURE is currently overvalued and has a potential downside of -5.81%.

Is NURE a buy, sell or hold?

Nuveen Short-Term REIT has no consensus analysts rating.

What are the forecasts/targets for the NURE price?

Issuer Target Up/Down from current
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 29.7 4.7%

Last update: 2025-08-06 04:42

NURE Fundamental Data Overview

Market Cap USD = 34.1m (34.1m USD * 1.0 USD.USD)
CCE Cash And Equivalents = unknown
Revenue TTM is 0, using Net Income TTM 0.0 + Cost of Revenue 0.0 = 0.0 USD
Beta = 1.04
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 34.1m USD (34.1m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = none (FCF TTM 0.0 / Enterprise Value 34.1m)
FCF Margin = unknown (Revenue TTM is 0)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 34.1m / Book Value Of Equity 0.0)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default)
NOPAT = 0.0 (EBIT 0.0, no tax applied on loss)
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown Debt (none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = none (Debt none / FCF TTM 0.0)
Total Stockholder Equity = unknown
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity none)
RoCE = unknown (Ebit 0.0 / (Equity none + L.T.Debt none))
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, Ebit 0.0)
WACC = unknown (E(34.1m)/V(0.0) * Re(8.16%)) + (D(none)/V(0.0) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 8.16% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)

Additional Sources for NURE ETF

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle